4//SEC Filing
REED ELIZABETH E 4
Accession 0001415889-25-003823
CIK 0001438533other
Filed
Feb 11, 7:00 PM ET
Accepted
Feb 12, 9:28 PM ET
Size
9.5 KB
Accession
0001415889-25-003823
Insider Transaction Report
Form 4
REED ELIZABETH E
Chief Legal Officer and GC
Transactions
- Exercise/Conversion
Common Stock
2025-02-10+8,000→ 97,482 total - Exercise/Conversion
Performance-based restricted stock units
2025-02-10−8,000→ 0 total→ Common Stock (8,000 underlying) - Sale
Common Stock
2025-02-12$23.53/sh−8,000$188,240→ 89,482 total
Footnotes (3)
- [F1]On January 31, 2022, the reporting person was granted performance restricted stock units (PSUs) covering 8,000 shares of the Issuer's common stock, to vest upon the satisfaction of certain clinical/regulatory performance criteria. On February 10, 2025, the PSUs vested upon the Issuer's confirmation that the clinical/regulatory performance criteria had been satisfied, including confirming a path forward for submitting an sNDA for traditional approval of FILSPARI (sparsentan) in FSGS.
- [F2]Each PSU represents a contingent right to receive one share of the common stock of the Issuer.
- [F3]This sale was made pursuant to a written plan adopted on March 15, 2024, meeting the requirements of Rule 10b5-1(c) of the Securities Exchange Act of 1934, as amended, and includes the sale of shares to cover the tax obligation that occurred upon the vesting of the PSUs.
Documents
Issuer
Travere Therapeutics, Inc.
CIK 0001438533
Entity typeother
Related Parties
1- filerCIK 0001283303
Filing Metadata
- Form type
- 4
- Filed
- Feb 11, 7:00 PM ET
- Accepted
- Feb 12, 9:28 PM ET
- Size
- 9.5 KB